MedTrace Logo

Blood Sample Collection to Evaluate Biomarkers for Hepatocellular Carcinoma

NCT03628651 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2150

Last updated 2020-08-06

No results posted yet for this study

Summary

The primary objective of this study is to obtain de-identified, clinically-characterized whole blood specimens for use in developing and evaluating the performance of new biomarker assays for detection of hepatocellular carcinoma (HCC).

Conditions

Interventions

OTHER

Blood Sample Collection

HCC subjects will have one blood sample collected.

OTHER

Blood Sample Collection

Surveillance subjects will have a blood sample collected and will be followed for up to 6 months. A second blood sample will be collected at the 6 month visit which will be scheduled no longer than 6 months from enrollment.

Sponsors & Collaborators

  • Exact Sciences Corporation

    lead INDUSTRY

Principal Investigators

  • Laura Strong · Exact Sciences

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-02
Primary Completion
2020-03-11
Completion
2020-03-11

Countries

  • United States
  • France
  • Germany
  • Italy
  • Spain
  • Taiwan
  • Thailand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03628651 on ClinicalTrials.gov